Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harpoon Therapeutics, Inc. - Common Stock (NQ: HARP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harpoon Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
7 Stocks to Add to Your 10x Watchlist
It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist. 
Via InvestorPlace
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Looking Into Harpoon Therapeutics's Recent Short Interest
Harpoon Therapeutics's (NASDAQ:HARP) short percent of float has risen 15.0% since its last report. The company recently reported that it has 563 thousand shares sold short, which is 3.22% of all... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday morning! 
Via InvestorPlace
Harpoon Therapeutics Shares Gain On Updated Data From Investigational Myeloma Drug
Via Benzinga
Expert Ratings for Harpoon Therapeutics
  Analysts have provided the following ratings for Harpoon Therapeutics (NASDAQ:HARP) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Dow Surges Over 250 Points; Weber Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
Stocks Hold Gains Ahead Of Tuesday's Economic Flurry
The major indexes are continuing their move higher this afternoon, as investors await tomorrow's release of November's consumer price index (CPI) data. 
Via Talk Markets
Three Small-Cap Biotech Stocks to Consider Now
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023 
Via MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
Why Is Reborn Coffee (REBN) Stock Up 34% Today?
Reborn Coffee (REBN) stock is heating up on Monday as investors take note of the California coffee company's shares with heavy trading. 
Via InvestorPlace
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development 
Via Spotlight Growth
Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?
Harpoon Therapeutics (HARP) stock is taking off on Monday following the release of updated results from its myeloma drug candidate. 
Via InvestorPlace
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022,... 
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
Harpoon adds experienced drug developer to leadership team 
From Harpoon Therapeutics
Via GlobeNewswire
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
Citigroup Maintains Buy Rating for Harpoon Therapeutics: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Harpoon Therapeutics (NASDAQ:HARP) and lower its price target from $7.00 to $6.00. Shares of Harpoon Therapeutics are trading down 3.78% over the... 
Via Benzinga
Analyst Ratings for Harpoon Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Harpoon Therapeutics (NASDAQ:HARP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.